<< Read Full Article
<< Read Full Article
Health stocks started the week on a mixed note amid a variety of clinical and regulatory news.
Acadia Pharmaceuticals (ACAD Quote) shares tanked Monday after the company said a midstage trial for schizophrenia drug ACP-104 didn't meet its primary or secondary endpoints.
Shares were down $3.67, or 43%, at $4.82. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet